Back to Search
Start Over
New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease
- Source :
- Infectious Diseases and Therapy, Vol 12, Iss 2, Pp 333-342 (2022)
- Publication Year :
- 2022
- Publisher :
- Adis, Springer Healthcare, 2022.
-
Abstract
- Abstract Cytomegalovirus (CMV) infection can have both direct and indirect effects after solid-organ transplantation, with a significant impact on transplant outcomes. Prevention strategies decrease the risk of CMV disease, although CMV still occurs in up to 50% of high-risk patients. Ganciclovir (GCV) and valganciclovir (VGCV) are the main drugs currently used for preventing and treating CMV. Emerging data suggest that letermovir is as effective as VGCV with fewer hematological side effects. Refractory and resistant CMV also still occur in solid-organ-transplant patients. Maribavir has been shown to be effective and have less toxicity in the treatment of refractory and resistant CMV. In this review paper, we discuss prevention strategies, refractory and resistant CMV, and drug-related side effects and their impact, as well as optimal use of novel anti-CMV therapies.
Details
- Language :
- English
- ISSN :
- 21938229 and 21936382
- Volume :
- 12
- Issue :
- 2
- Database :
- Directory of Open Access Journals
- Journal :
- Infectious Diseases and Therapy
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.4a85663f5d1473c89454ee3497fc1e9
- Document Type :
- article
- Full Text :
- https://doi.org/10.1007/s40121-022-00746-1